熱門資訊> 正文
生物GAAP每股收益攀升-0.31美元
2025-05-14 21:53
- Climb Bio press release (NASDAQ:CLYM): Q1 GAAP EPS of -$0.31.
- Cash Position: Cash, cash equivalents and marketable securities were $197.8 million as of March 31, 2025. Cash, cash equivalents and marketable securities are expected to fund operations through 2027.
More on Climb Bio
- Seeking Alpha’s Quant Rating on Climb Bio
- Historical earnings data for Climb Bio
- Financial information for Climb Bio
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
